Zogenix (NASDAQ:ZGNX) was downgraded by investment analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Tuesday.
A number of other equities analysts have also recently weighed in on the company. Zacks Investment Research cut Zogenix from a “hold” rating to a “sell” rating in a report on Thursday, June 21st. Mizuho reissued a “buy” rating and set a $51.00 price objective on shares of Zogenix in a report on Thursday, May 10th. ValuEngine raised Zogenix from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Finally, Leerink Swann reissued an “outperform” rating on shares of Zogenix in a report on Sunday, March 4th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $53.20.
Shares of NASDAQ ZGNX opened at $42.60 on Tuesday. The stock has a market cap of $1.52 billion, a P/E ratio of -10.60 and a beta of 1.76. Zogenix has a 1-year low of $10.05 and a 1-year high of $48.75.
In other Zogenix news, EVP Gail M. Farfel sold 5,118 shares of Zogenix stock in a transaction that occurred on Tuesday, June 12th. The stock was sold at an average price of $45.00, for a total value of $230,310.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.60% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in ZGNX. Two Sigma Advisers LP bought a new stake in shares of Zogenix in the 4th quarter worth approximately $1,778,000. State of Wisconsin Investment Board grew its position in shares of Zogenix by 66.3% in the 4th quarter. State of Wisconsin Investment Board now owns 31,600 shares of the company’s stock worth $1,266,000 after buying an additional 12,600 shares during the last quarter. Swiss National Bank bought a new stake in shares of Zogenix in the 4th quarter worth approximately $2,043,000. Rhumbline Advisers grew its position in shares of Zogenix by 5.1% in the 1st quarter. Rhumbline Advisers now owns 34,097 shares of the company’s stock worth $1,366,000 after buying an additional 1,659 shares during the last quarter. Finally, Deutsche Bank AG grew its position in shares of Zogenix by 59.5% in the 4th quarter. Deutsche Bank AG now owns 1,036,964 shares of the company’s stock worth $41,529,000 after buying an additional 386,867 shares during the last quarter.
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.